{"Exaggerate": "The claim may exaggerate the extent of the Canadian government's approval of psilocybin therapy. The expert's verdict clarifies that only a limited number of patients with incurable cancer were allowed to receive psilocybin therapy, and there are currently no approved therapeutic products containing psilocybin available to the general public.", "Understate": "The claim may understate the limitations and restrictions surrounding the use of psilocybin therapy. The expert's verdict explains that psilocybin therapy is not widely accessible in Canada, and there are no approved therapeutic psilocybin products available. It also mentions that the medical exemptions allowing psilocybin therapy may not continue to be allowed by health officials.", "Lack enough support": "The claim may lack sufficient support for its assertion that psilocybin therapy has been approved by the Canadian government for easing anxiety and depression associated with a terminal diagnosis. The expert's verdict clarifies that while some exemptions have been granted for specific cases, there are no approved therapeutic products containing psilocybin available in Canada.", "Problematic assumption": "The claim may make the problematic assumption that the Canadian government has fully approved the use of psilocybin therapy for anxiety and depression associated with a terminal diagnosis. The expert's verdict highlights that the exemptions granted for psilocybin therapy are limited and not widely accessible.", "Exist alternative explanation": "The claim may not consider alternative explanations or perspectives regarding the use of psilocybin therapy. The expert's verdict provides additional information about the legal status of psilocybin and the ongoing research on its potential therapeutic benefits."}